Caredx, INC. (CDNA) — SEC Filings

Q: What are the key financial highlights for Caredx, INC.?

Key financial highlights for Caredx, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Caredx, INC.?

Key executives at Caredx, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Caredx, INC. stock?

Risk factors for Caredx, INC. (CDNA) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Caredx, INC.?

Forward-looking statements and predictions from Caredx, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Caredx, INC.. Recent 8-K/A filing on Apr 23, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Caredx, INC. on SEC EDGAR

Overview

Caredx, INC. (CDNA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K/A filed on Apr 23, 2026: CareDx, Inc. filed an 8-K/A amendment on April 23, 2026, related to events occurring on April 20, 2026. The filing specifically addresses Item 5.02, concerning the departure of directors or certain officers, the election of directors, and the appointment of certain officers, as well as compensatory

Sentiment Summary

Across 43 filings, the sentiment breakdown is: 2 bullish, 39 neutral, 2 mixed. The dominant filing sentiment for Caredx, INC. is neutral.

Filing Type Overview

Caredx, INC. (CDNA) has filed 1 8-K/A, 19 8-K, 6 10-Q, 2 DEF 14A, 1 10-K, 12 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (43)

CareDx, Inc. Amends 8-K Filing on Officer/Director Changes — 8-K/A · Apr 23, 2026 Risk: medium
CareDx, Inc. filed an 8-K/A amendment on April 23, 2026, related to events occurring on April 20, 2026. The filing specifically addresses Item 5.02, concerning
8-K Filing — 8-K · Apr 16, 2026
CareDx, Inc. Files 8-K Report — 8-K · Dec 18, 2025 Risk: low
On December 18, 2025, CareDx, Inc. filed a Form 8-K to report an event under "Other Events." The filing does not contain specific details about the event itself
8-K Filing — 8-K · Dec 15, 2025
CareDx Swings to Profit in Q3 on Strong Revenue Growth — 10-Q · Nov 4, 2025 Risk: medium
CareDx, Inc. (CDNA) reported a net income of $1.675 million for the three months ended September 30, 2025, a significant improvement from a net loss of $10.637
CareDx Announces Board and Executive Changes — 8-K · Oct 24, 2025 Risk: medium
CareDx, Inc. announced on October 22, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company reported the de
CareDx Q2 Revenue Dips to $70.1M, Net Loss Narrows to $20.3M — 10-Q · Aug 6, 2025 Risk: medium
CareDx, Inc. reported total revenue of $70.1 million for the three months ended June 30, 2025, a decrease from $74.5 million in the prior-year period. For the s
CareDx, Inc. Files 8-K: Director Changes & Officer Compensation Updates — 8-K · Jun 12, 2025 Risk: medium
On June 12, 2025, CareDx, Inc. filed an 8-K report detailing several key events. These include the departure of a director, the election of new directors, and u
CareDx, Inc. Files 8-K Report — 8-K · Jun 3, 2025 Risk: low
On June 3, 2025, CareDx, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures, other events, and financial statements and exhibits.
CareDx Files Q1 2025 10-Q — 10-Q · Apr 30, 2025 Risk: medium
CareDx, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025
CareDx (CDNA) DEF 14A: Executive Compensation Details — DEF 14A · Apr 28, 2025 Risk: low
CareDx, Inc. filed a DEF 14A on April 28, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and board member informa
CareDx Files 8-K: Officer/Director Changes & Financials — 8-K · Mar 28, 2025 Risk: medium
CareDx, Inc. filed an 8-K on March 28, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers
CareDx, Inc. Files 2024 Annual Report — 10-K · Feb 28, 2025 Risk: medium
CareDx, Inc. filed its 10-K for the fiscal year ending December 31, 2024, reporting on its operations in medical diagnostics. The company, formerly known as XDx
CareDx Files 8-K on Financials and Operations — 8-K · Feb 26, 2025 Risk: low
CareDx, Inc. filed an 8-K on February 26, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosur
CareDx Files 8-K on Financials and Operations — 8-K · Jan 13, 2025 Risk: low
CareDx, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes disclosures related to R
CareDx CFO Departs; New Directors Appointed — 8-K · Jan 8, 2025 Risk: medium
CareDx, Inc. announced on January 6, 2025, the departure of its Chief Financial Officer, Michael McCarty, effective January 10, 2025. The company also announced
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
SC 13G/A Filing — SC 13G/A · Nov 8, 2024
SC 13G/A Filing — SC 13G/A · Nov 5, 2024
CareDx, Inc. Files Q3 2024 10-Q Report — 10-Q · Nov 4, 2024 Risk: medium
CareDx, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third quarter of
SC 13G/A Filing — SC 13G/A · Oct 17, 2024
CareDx, Inc. Files 8-K on Financials — 8-K · Oct 15, 2024 Risk: low
On October 15, 2024, CareDx, Inc. filed an 8-K report detailing results of operations and financial condition, along with Regulation FD disclosures and financia
CareDx, Inc. Files 8-K for Other Events — 8-K · Oct 8, 2024 Risk: medium
On October 7, 2024, CareDx, Inc. filed an 8-K report. The filing indicates that the company is providing information related to "Other Events" as of October 7,
CareDx Reports Director/Officer Changes & Financials — 8-K · Oct 4, 2024 Risk: medium
CareDx, Inc. filed an 8-K on October 4, 2024, reporting on the departure of directors, election of new directors, appointment of officers, and compensatory arra
CareDx Announces Board Changes and Executive Compensation Update — 8-K · Sep 12, 2024 Risk: medium
CareDx, Inc. announced on September 6, 2024, a series of significant corporate actions. These include the departure of Director Dr. Robert L. Brush, the electio
SC 13G/A Filing — SC 13G/A · Aug 21, 2024
CareDx, Inc. Files Q2 2024 10-Q Report — 10-Q · Jul 31, 2024 Risk: medium
CareDx, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results for the second quarter and the first half of 2024, detai
CareDx, Inc. Files 8-K on Shareholder Votes and Financials — 8-K · Jun 18, 2024 Risk: low
On June 13, 2024, CareDx, Inc. filed an 8-K report detailing the submission of matters to a vote of security holders and financial statements. The filing also i
CareDx, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: medium
CareDx, Inc. (CDNA) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. CareDx, Inc. filed a 10-Q report for the period ending March 31, 2024. The fili
CareDx, Inc. Files Definitive Proxy Statement (DEF 14A) — DEF 14A · Apr 29, 2024 Risk:
CareDx, Inc. (CDNA) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. CareDx, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 29, 202
CareDx Appoints New CMO, Adds Director — 8-K · Apr 16, 2024 Risk: medium
CareDx, Inc. announced on April 15, 2024, the appointment of Dr. Veronica Miller as Chief Medical Officer and the election of Dr. Michael J. Hostetter to its Bo
CareDx Appoints New CMO, Adds Directors — 8-K · Mar 11, 2024 Risk: medium
CareDx, Inc. announced on March 9, 2024, the appointment of Dr. Veronica S. Hipólito as Chief Medical Officer and the election of Dr. Hipólito and Dr. Robert L.
CareDx Files 8-K on Financial Condition and Operations — 8-K · Feb 28, 2024 Risk: low
CareDx, Inc. filed an 8-K on February 28, 2024, reporting on its results of operations and financial condition, along with a Regulation FD Disclosure. The filin
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
Nikko Asset Management Americas Takes 3.5% Passive Stake in CareDx — SC 13G · Feb 12, 2024 Risk: low
Nikko Asset Management Americas, Inc. has reported an initial passive stake in CareDx, Inc. (NASDAQ: CDNA) as of December 31, 2023. This filing indicates that N
Sumitomo Mitsui Trust Discloses Stake in CareDx (CDNA) — SC 13G · Feb 5, 2024
Sumitomo Mitsui Trust Holdings, Inc. (SMTH) filed an initial SC 13G on February 5, 2024, disclosing its ownership in CareDx, Inc. (CDNA) as of December 31, 2023
ARK Investment Management Holds 10.9% Stake in CareDx — SC 13G/A · Jan 29, 2024
ARK Investment Management LLC, led by Cathie Wood, filed an amended SC 13G/A on January 29, 2024, disclosing its ownership in CareDx, Inc. As of December 31, 20
BlackRock Updates Passive Stake in CareDx Inc. (Amendment No. 6) — SC 13G/A · Jan 24, 2024
BlackRock Inc. filed an amended SC 13G/A on January 24, 2024, indicating its ownership of CareDx Inc. common stock as of December 31, 2023. This filing, Amendme
State Street Corp Amends CareDx Stake Filing — SC 13G/A · Jan 10, 2024
State Street Corp, a major financial institution, filed an amended Schedule 13G/A on January 10, 2024, indicating its ownership of CareDx, Inc. common stock as
CareDx Files 8-K on Operations & Financial Condition — 8-K · Jan 9, 2024
CareDx, Inc. filed an 8-K on January 9, 2024, to report on its results of operations and financial condition, as well as Regulation FD disclosure. This filing i

Risk Profile

Risk Assessment: Of CDNA's 26 recent filings, 0 were flagged as high-risk, 17 as medium-risk, and 9 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Caredx, INC.'s most recent 10-Q filing (Nov 4, 2025):

Revenue: $100.055M
Net Income: $1.675M
EPS: $0.03
Debt-to-Equity: 0.39
Cash Position: $91.435M
Operating Margin: -0.2%
Total Assets: $432.307M
Total Debt: $121.167M

Key Executives

Mr. John W. Hanna
Mr. Keith Kennedy
Ms. Jessica Meng
Michael McCarty
Dr. Alex Wong
Dr. Michael J. Hostetter
Ms. Jennifer L. McNeely
Dr. Robert L. Brush
Dr. David E. R. Sutherland
Dr. John L. Watts
Mr. Johnson
Dr. Seeto
Dr. Veronica Miller
Dr. John L. Reynolds
Dr. Veronica S. Hipólito

Industry Context

CareDx operates in the specialized field of transplant diagnostics and digital health solutions. The industry is characterized by rapid technological advancements, a strong focus on clinical validation, and a complex regulatory environment. Key competitors often focus on specific areas like organ rejection monitoring or patient management post-transplant. Trends include the increasing adoption of non-invasive testing methods and integrated digital platforms to improve patient outcomes and streamline healthcare processes.

Top Tags

financial-reporting (5) · institutional-ownership (5) · amendment (4) · 10-Q (4) · financials (4) · corporate-governance (4) · 8-K (3) · disclosure (3) · executive-compensation (3) · board-changes (3)

Executive Compensation

From the most recent DEF 14A filing (Apr 29, 2024):

Mr. Johnson — Member
Dr. Seeto — Member

Key Numbers

Commission File Number: 001-36536 — Identifies the company's SEC filings.
IRS Employer Identification No.: 94-3316839 — Company's tax identification number.
Net Income: $1.675M — Q3 2025, a swing from a $10.637M loss in Q3 2024
Total Revenue: $100.055M — Q3 2025, up 20.7% from $82.883M in Q3 2024
Testing Services Revenue: $72.168M — Q3 2025, up 18.7% from Q3 2024
Product Revenue: $12.478M — Q3 2025, up 22.2% from Q3 2024
Patient and Digital Solutions Revenue: $15.409M — Q3 2025, up 29.9% from Q3 2024
Accrued Litigation Settlement Expense: $20.250M — As of September 30, 2025, a new liability
Cash and Cash Equivalents: $91.435M — As of September 30, 2025, down from $114.689M at Dec 31, 2024
Common Stock Repurchases: $75.563M — Nine months ended September 30, 2025, contributing to cash outflow
Accumulated Deficit: $719.047M — As of September 30, 2025, indicating historical losses
Shares Outstanding: 51,432,639 — As of October 30, 2025
SEC File Number: 001-36536 — Identifies the company's filing with the SEC.
Q2 2025 Total Revenue: $70.1M — Decreased from $74.5M in Q2 2024, indicating a 5.9% decline.
Q2 2025 Net Loss: $20.3M — Improved from a $25.1M net loss in Q2 2024, showing a 19.1% reduction in loss.

Forward-Looking Statements

{"claim":"Other institutional investors may take notice of Nikko Asset Management Americas' stake and potentially initiate or increase their own positions in CareDx, Inc.","entity":"CareDx, Inc.","targetDate":"Q1 2024","confidence":"medium"}

Related Companies

NTRA

Frequently Asked Questions

What are the latest SEC filings for Caredx, INC. (CDNA)?

Caredx, INC. has 43 recent SEC filings from Jan 2024 to Apr 2026, including 19 8-K, 12 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of CDNA filings?

Across 43 filings, the sentiment breakdown is: 2 bullish, 39 neutral, 2 mixed. The dominant sentiment is neutral.

Where can I find Caredx, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Caredx, INC. (CDNA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Caredx, INC.?

Key financial highlights from Caredx, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for CDNA?

The investment thesis for CDNA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Caredx, INC.?

Key executives identified across Caredx, INC.'s filings include Mr. John W. Hanna, Mr. Keith Kennedy, Ms. Jessica Meng, Michael McCarty, Dr. Alex Wong and 11 others.

What are the main risk factors for Caredx, INC. stock?

Of CDNA's 26 assessed filings, 0 were flagged high-risk, 17 medium-risk, and 9 low-risk.

What are recent predictions and forward guidance from Caredx, INC.?

Recent forward-looking statements from Caredx, INC. include guidance on {"claim":"Other institutional investors may take notice of Nikko Asset Management Americas' stake and potentially initia.